Fishman Carbon AMCAS Limited Reports Q1 FY27 Results; Posts Net Loss of Rs 57.88 Crore
Dishman Carbogen Amcis Limited (DCAL) has presented its Q1 FY27 performance and business outlook in its latest investor presentation for the quarter ended June 30, 2026. The presentation highlights a mixed quarter, with revenue and profitability affected by the postponement of certain CDMO project deliveries, while the Marketable Molecules business delivered strong growth.
At the same time, the company continues to build its position as a global integrated contract development and manufacturing organisation (CDMO), with a strong R&D pipeline, global manufacturing footprint and exposure to complex and high-value pharmaceutical products.
Q1 FY27 Performance: Revenue Moderates
Dishman Carbogen Amcis reported net revenue of ₹6,776 million in Q1 FY27, compared with ₹7,081 million in Q1 FY26, representing a 4.3% year-on-year decline.
The decline was primarily related to the CDMO business. According to the presentation, project deliverables worth approximately CHF 10 million were rescheduled by a customer to the second half of the financial year.
This timing issue affected the quarter’s revenue even though the underlying projects were not cancelled.
Marketable Molecules Business Delivers Strong Growth
While the CDMO business faced a temporary revenue deferment, the company’s Marketable Molecules (MM) segment performed strongly.
Revenue from Marketable Molecules increased 48% year-on-year in Q1 FY27, primarily driven by higher Cholesterol revenue. The segment generated approximately ₹1,433 million, compared with ₹968 million in the corresponding quarter last year.
This growth provided a partial offset to the decline in CDMO revenue.
Profitability Under Pressure
The biggest challenge during the quarter was profitability.
Dishman Carbogen Amcis reported EBITDA of ₹601 million, down from ₹1,407 million in Q1 FY26. The EBITDA margin declined sharply to 8.9% from 19.9%.
The company explained that the CDMO margin declined because revenue was deferred while a large portion of the cost base remained fixed. A notional foreign-exchange loss of approximately ₹117.3 million also affected margins.
The CDMO segment’s EBITDA margin fell to 6.3% from 17.9%, while the Marketable Molecules margin stood at 18.6%, compared with 32.4% a year earlier. The company noted that the MM margin was broadly in line with its FY26 full-year margin, with the change in product mix toward Cholesterol affecting the quarter.
Loss at Profit After Tax Level
The weaker operating performance also affected the bottom line.
Profit before tax moved from a profit of ₹387 million in Q1 FY26 to a loss of ₹512 million in Q1 FY27.
Profit after tax stood at a loss of ₹579 million, compared with a profit of ₹234 million in the year-ago quarter.
The quarterly numbers therefore reflect significant short-term pressure, although the company attributes a major part of the weakness to timing and project-delivery factors.
CDMO Remains the Core Business
Dishman Carbogen Amcis describes itself as a fully integrated CDMO with capabilities ranging from process research and development to late-stage clinical and commercial manufacturing and API supply to innovator pharmaceutical companies.
The company operates across India, Switzerland, the UK, France, the Netherlands and China, giving it a global development and manufacturing footprint. Its portfolio includes APIs, high-potent APIs, intermediates, Vitamin D analogues, Cholesterol and other specialised products.
The integrated model allows the company to work with customers through different stages of the drug-development lifecycle.
Strong R&D and Manufacturing Infrastructure
One of Dishman’s key competitive advantages is its combination of R&D and manufacturing capabilities.
The company highlights:
- 23 multi-purpose manufacturing facilities globally
- 32 R&D and high-potency laboratories
- More than 2,200 employees
- 950+ dedicated R&D scientists
- Around 50% of technical staff holding PhDs
- More than 250 clients
- Operations across six countries
- Facilities recognised or approved by global health authorities including USFDA, MEB, Swissmedic, ANSM, WHO, MFDS, PMDA, NMPA and EDQM.
The company also has approximately 7,500 square metres of R&D space across Switzerland, Manchester and Bavla.
Its manufacturing infrastructure includes significant reactor capacity at Bavla, Naroda and Shanghai, as well as a new 9,500-square-metre sterile injectable facility in France.
Drug Development Pipeline Provides Long-Term Opportunity
Despite the weak Q1 financial performance, the company’s pipeline remains an important part of the investment story.
Dishman highlighted a CHF 89 million new product development pipeline and a strong basket of 13 molecules in late Phase III development.
The presentation also states that two oncology molecules have entered late Phase III, while the company has 29 commercialised molecules.
The transition of molecules from development into commercial manufacturing can create opportunities for longer-term recurring business if projects successfully progress through clinical and regulatory stages.
Focus on Oncology and High-Potency Drugs
Dishman sees significant opportunity in specialised medicines, particularly oncology.
The presentation notes that oncology remains the largest therapy area in terms of projected global spending and expects growth in the segment as new treatments are launched.
The company currently has multiple molecules in late-stage development, with several of them focused on oncology.
This is strategically relevant because oncology products often require specialised manufacturing capabilities, including high-potency API handling.
Bioconjugation and ADC Capabilities
Another area highlighted in the presentation is ADC and bioconjugation.
Dishman has integrated capabilities covering:
- Drug linker manufacturing
- Bulk drug substance manufacturing
- Drug product manufacturing
- Process development and validation
- Quality-control and analytical development
- GMP manufacturing
- Stability studies
- Regulatory support
The company says it has received multiple quotations from different customers and is discussing additional alliances, while also working with start-up companies.
The growing interest in targeted therapies and complex biologics could provide an additional opportunity for companies with specialised bioconjugation capabilities.
Capacity Utilisation Remains a Key Focus
Dishman is also focused on improving utilisation of its existing manufacturing capacity.
The company plans to target small and mid-sized global biotechnology companies while expanding into new geographies.
Its large-scale manufacturing infrastructure can potentially help it secure larger and longer-term contracts as capacity utilisation improves.
This will be particularly important after the Q1 revenue deferments, as better utilisation can help improve operating leverage.
Capex and Debt
Dishman added approximately CHF 4.9 million of capital expenditure during Q1 FY27.
Net debt excluding lease liabilities stood at CHF 153.6 million as of June 30, 2026, compared with CHF 146.8 million as of March 31, 2026.
Investors will therefore need to monitor the company’s capital expenditure, debt levels and cash generation alongside its growth investments.
Long-Term Business Opportunity
Dishman’s historical performance shows a significant increase in operating revenue over the longer term. Revenue from operations increased from ₹19,120 million in FY21 to ₹29,319 million in FY26.
EBITDA increased from ₹2,743 million in FY21 to ₹5,656 million in FY26, while the EBITDA margin improved from 14.3% to 19.3% over the same period.
The Q1 FY27 performance therefore represents a significant short-term setback compared with the company’s recent profitability trend.
What Investors Should Watch
For investors tracking Dishman Carbogen Amcis, the key factors to monitor over the coming quarters include:
- Recovery of deferred CDMO revenue
- CDMO capacity utilisation
- New product development pipeline
- Progress of late Phase III molecules
- Growth in Marketable Molecules
- Oncology and high-potency API opportunities
- ADC and bioconjugation business
- New customer additions
- EBITDA margin recovery
- Foreign-exchange impact
- Capex and net debt
The company’s ability to convert its development pipeline into commercial manufacturing contracts will be particularly important for its medium- and long-term growth.
Point to considered
Dishman Carbogen Amcis’ Q1 FY27 investor presentation presents a mixed picture.
The quarter was weak financially, with revenue declining 4.3%, EBITDA falling 57.3%, and the company reporting a ₹579 million loss after tax.
However, the underlying business continues to have several potential growth drivers. Marketable Molecules revenue increased 48%, the company has a CHF 89 million new product development pipeline, and 13 molecules are in late Phase III development.
The near-term story will depend heavily on the timing of deferred CDMO projects and recovery in margins. Over the longer term, the company’s global CDMO platform, specialised chemistry capabilities, oncology exposure, R&D pipeline and bioconjugation capabilities could provide opportunities for renewed growth.
Disclaimer: This article is based on Dishman Carbogen Amcis Limited’s Q1 FY27 Investor Presentation for the quarter ended June 30, 2026. The article is for informational purposes only and should not be considered investment advice or a recommendation to buy or sell any security. Figures and forward-looking statements are based on information presented by the company and may be subject to change.